Clinical trial
DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia…
NCT00302341 · Immtech Pharmaceuticals, Inc, Industry · Terminated
Key facts
| NCT number | NCT00302341 |
|---|---|
| Title | DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP) |
| Official title | International Randomized, Controlled Phase 3 Trial of DB289 Versus Trimethoprim-sulfamethoxazole for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP) in Patients With HIV/AIDS |
| Lead sponsor | Immtech Pharmaceuticals, Inc, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pneumonia, Interstitial Plasma Cell, Pneumocystis Carinii Pneumonia, Pneumocystis Carinii, HIV Infections |
| Intervention type | Drug |
| Interventions | Pafuramidine maleate (DB289), Trimethoprim-Sulfamethoxazole (TMP-SMX) |
| Enrollment | 48 |
| Start date | May 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Mar 14, 2006 |
| Last update posted | Mar 7, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: